glp-1 side effects and risks Press Release Page Part 2 of a 3-Part

Who Should Avoid GLP-1 Medications Even with a high BMI, not everyone is eligible for semaglutide or tirzepatide medications

These findings suggest that exendin 939 may be less likely to cause adverse effects associated with thermoregulation, such as hyperthermia or hypothermia, as observed with previous TRPV1 antagonists

Fagerberg B, Edwards S, Halmos T et al (2005) Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

High-Risk Demographic Targets: The vast majority of patients within the study who experienced active ischemic events fell into specific baseline sub-groups: predominantly men, or individuals between the ages of 50 and 65